

Evren Alici

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/147082/publications.pdf>

Version: 2024-02-01

47
papers

1,928
citations

394421

19
h-index

254184

43
g-index

48
all docs

48
docs citations

48
times ranked

3388
citing authors

#	ARTICLE	IF	CITATIONS
1	Autologous antitumor activity by NK cells expanded from myeloma patients using GMP-compliant components. <i>Blood</i> , 2008, 111, 3155-3162.	1.4	171
2	The Role of CXC Chemokine Receptors 1â€“4 on Immune Cells in the Tumor Microenvironment. <i>Frontiers in Immunology</i> , 2018, 9, 2159.	4.8	158
3	Natural Killer Cell-Based Therapies Targeting Cancer: Possible Strategies to Gain and Sustain Anti-Tumor Activity. <i>Frontiers in Immunology</i> , 2015, 6, 605.	4.8	153
4	CD73 immune checkpoint defines regulatory NK cells within the tumor microenvironment. <i>Journal of Clinical Investigation</i> , 2020, 130, 1185-1198.	8.2	139
5	Clinical-grade, large-scale, feeder-free expansion of highly active human natural killer cells for adoptive immunotherapy using an automated bioreactor. <i>Cytotherapy</i> , 2010, 12, 1044-1055.	0.7	112
6	Infectious complications and NK cell depletion following daratumumab treatment of Multiple Myeloma. <i>PLoS ONE</i> , 2019, 14, e0211927.	2.5	85
7	NK cell-mediated targeting of human cancer and possibilities for new means of immunotherapy. <i>Cancer Immunology, Immunotherapy</i> , 2008, 57, 1541-1552.	4.2	74
8	Thioredoxin activity confers resistance against oxidative stress in tumor-infiltrating NK cells. <i>Journal of Clinical Investigation</i> , 2020, 130, 5508-5522.	8.2	52
9	The Use of Novel Drugs Can Effectively Improve Response, Delay Relapse and Enhance Overall Survival in Multiple Myeloma Patients with Renal Impairment. <i>PLoS ONE</i> , 2014, 9, e101819.	2.5	49
10	Anti-myeloma activity of endogenous and adoptively transferred activated natural killer cells in experimental multiple myeloma model. <i>Experimental Hematology</i> , 2007, 35, 1839-1846.	0.4	47
11	Boosting Natural Killer Cell-Mediated Targeting of Sarcoma Through DNAM-1 and NKG2D. <i>Frontiers in Immunology</i> , 2020, 11, 40.	4.8	40
12	Proteasome inhibitors and <scp>IM</scp>iDs can overcome some highâ€“risk cytogenetics in multiple myeloma but not gain 1q21. <i>European Journal of Haematology</i> , 2016, 96, 46-54.	2.2	35
13	Generation of Retinal Pigment Epithelial Cells Derived from Human Embryonic Stem Cells Lacking Human Leukocyte Antigen Class I and II. <i>Stem Cell Reports</i> , 2020, 14, 648-662.	4.8	35
14	Visualization of 5T33 myeloma cells in the C57BL/KaLwRij mouse: establishment of a new syngeneic murine model of multiple myeloma. <i>Experimental Hematology</i> , 2004, 32, 1064-1072.	0.4	30
15	Translocation (11;14) in newly diagnosed multiple myeloma, time to reclassify this standard risk chromosomal aberration?. <i>European Journal of Haematology</i> , 2019, 103, 588-596.	2.2	24
16	IPH-2101, a fully human anti-NK-cell inhibitory receptor mAb for the potential treatment of hematological cancers. <i>Current Opinion in Molecular Therapeutics</i> , 2010, 12, 724-33.	2.8	24
17	Functional Assessment for Clinical Use of Serum-Free Adapted NK-92 Cells. <i>Cancers</i> , 2019, 11, 69.	3.7	21
18	Wnt/Î²-Catenin Stimulation and Laminins Support Cardiovascular Cell Progenitor Expansion from Human Fetal Cardiac Mesenchymal Stromal Cells. <i>Stem Cell Reports</i> , 2016, 6, 607-617.	4.8	20

#	ARTICLE	IF	CITATIONS
19	Autologous NK cells as consolidation therapy following stem cell transplantation in multiple myeloma. <i>Cell Reports Medicine</i> , 2022, 3, 100508.	6.5	20
20	Re-challenging with anti-CD38 monotherapy in triple refractory multiple myeloma patients is a feasible and safe approach. <i>British Journal of Haematology</i> , 2016, 174, 473-477.	2.5	19
21	Independent control of natural killer cell responsiveness and homeostasis at steady-state by CD11c+ dendritic cells. <i>Scientific Reports</i> , 2016, 6, 37996.	3.3	18
22	NK cell frequencies, function and correlates to vaccine outcome in BNT162b2 mRNA anti-SARS-CoV-2 vaccinated healthy and immunocompromised individuals. <i>Molecular Medicine</i> , 2022, 28, 20.	4.4	18
23	Perforin Promotes Amyloid Beta Internalisation in Neurons. <i>Molecular Neurobiology</i> , 2017, 54, 874-887.	4.0	17
24	Outcome of COVID-19 in multiple myeloma patients in relation to treatment. <i>European Journal of Haematology</i> , 2020, 105, 751-754.	2.2	17
25	Pharmacogenetic study of the impact of ABCB1 single-nucleotide polymorphisms on lenalidomide treatment outcomes in patients with multiple myeloma: results from a phase IV observational study and subsequent phase II clinical trial. <i>Cancer Chemotherapy and Pharmacology</i> , 2018, 81, 183-193.	2.3	16
26	GMP Facilities for Manufacturing of Advanced Therapy Medicinal Products for Clinical Trials: An Overview for Clinical Researchers. <i>Current Gene Therapy</i> , 2010, 10, 508-515.	2.0	15
27	Direct evidence for a polygenic etiology in familial multiple myeloma. <i>Blood Advances</i> , 2017, 1, 619-623.	5.2	15
28	Engineered NK Cells Against Cancer and Their Potential Applications Beyond. <i>Frontiers in Immunology</i> , 2022, 13, 825979.	4.8	14
29	Up-regulation of DNAM-1 and NKp30, associated with improvement of NK cells activation after long-term culture of mononuclear cells from patients with ovarian neoplasia. <i>Human Immunology</i> , 2014, 75, 777-784.	2.4	11
30	Upfront bortezomib, lenalidomide, and dexamethasone compared to bortezomib, cyclophosphamide, and dexamethasone in multiple myeloma. <i>European Journal of Haematology</i> , 2019, 103, 247-254.	2.2	11
31	Retroviral Gene Transfer into Primary Human Natural Killer Cells. <i>Methods in Molecular Biology</i> , 2009, 506, 127-137.	0.9	11
32	Short-term IL-15 priming leaves a long-lasting signalling imprint in mouse NK cells independently of a metabolic switch. <i>Life Science Alliance</i> , 2021, 4, e202000723.	2.8	9
33	Phosphodiesterase 4A confers resistance to PGE ₂ -mediated suppression in CD25 ⁺ /CD54 ⁺ NK cells. <i>EMBO Reports</i> , 2021, 22, e51329.	4.5	8
34	Low dose venetoclax as a single agent treatment of plasma cell malignancies harboring t(11;14). <i>American Journal of Hematology</i> , 2021, 96, 925-933.	4.1	7
35	Antibody response to COVID-19 mRNA vaccine (Comirnaty) in myeloma patients treated with high-dose melphalan and/or immunotherapy. <i>American Journal of Hematology</i> , 2021, 96, E443-E446.	4.1	7
36	Deletion of Chromosomal Region 8p21 Confers Resistance to Bortezomib and Is Associated with Upregulated Decoy TRAIL Receptor Expression in Patients with Multiple Myeloma. <i>PLoS ONE</i> , 2015, 10, e0138248.	2.5	7

#	ARTICLE	IF	CITATIONS
37	Characterization of human natural killer cells for therapeutic use. <i>Cytotherapy</i> , 2019, 21, 315-326.	0.7	5
38	Dynamic follow-up of smoldering multiple myeloma identifies a subset of patients at high risk of progression. <i>American Journal of Hematology</i> , 2021, 96, E63-E65.	4.1	5
39	Comparative evaluation of involved free light chain and monoclonal spike as markers for progression from monoclonal gammopathy of undetermined significance to multiple myeloma. <i>American Journal of Hematology</i> , 2021, 96, 23-30.	4.1	5
40	Disclosing the Parameters Leading to High Productivity of Retroviral Producer Cells Lines: Evaluating Random Versus Targeted Integration. <i>Human Gene Therapy Methods</i> , 2017, 28, 78-90.	2.1	4
41	Characterization of Stem-Like Cells in Mucoepidermoid Tracheal Paediatric Tumor. <i>PLoS ONE</i> , 2014, 9, e107712.	2.5	2
42	Predicting Drug Resistance by Single-Cell RNASeq in Patients with Multiple Myeloma. <i>Clinical Chemistry</i> , 2021, 67, 1309-1311.	3.2	2
43	Lenalidomide versus lenalidomide+dexamethasone prolonged treatment after second-line lenalidomide+dexamethasone induction in multiple myeloma. <i>Cancer Medicine</i> , 2018, 7, 2256-2268.	2.8	1
44	Improved survival in multiple Myeloma patients undergoing autologous stem cell transplantation is entirely in the standard cytogenetic risk groups. <i>European Journal of Haematology</i> , 2021, 106, 546-554.	2.2	1
45	The Rev II Trial: Lenalidomide and Dexamethasone As Second Line Treatment in Myeloma Followed By Extended Lenalidomid Vs Len/Dex. <i>Blood</i> , 2015, 126, 3047-3047.	1.4	1
46	The Effect of Mesenchymal Stromal Cells Derived From Endometriotic Lesions on Natural Killer Cell Function. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 612714.	3.7	1
47	Ex Vivo Activity of Immunotherapeutic Approaches Targeting CD38 Against Daratumumab-Resistant Multiple Myeloma Patient Samples. <i>Blood</i> , 2019, 134, 1848-1848.	1.4	0